Skip to main content
BNTX
NASDAQ Life Sciences

BioNTech 公布第四季度巨额亏损，收入暴跌由弱势疫苗销售所致

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$86.75
Mkt Cap
$24.565B
52W Low
$81.2
52W High
$124
Market data snapshot near publication time

summarizeSummary

BioNTech 公布其 2025 年第四季度财务表现出现显著下滑，收入从前一年同期的 1,190.0 亿欧元下降到 907.4 亿欧元，主要由新冠疫苗需求减少所驱动。该公司还公布了第四季度巨额的 IFRS 净亏损，达到 305.0 亿欧元，这与 2024 年同期 259.5 亿欧元的盈利形成鲜明对比，且全年 IFRS 净亏损扩大至 1,136.1 亿欧元。该财报在 BioNTech 公布其雄心勃勃的肿瘤学产品线扩张计划以及其联合创始人离职的最近声明之后提供了至关重要的财务背景。其成熟疫苗业务的利润恶化和收入下滑具有实质性意义，表明 BioNTech 在转型为多产品肿瘤学公司的过程中面临的挑战。交易者将密切关注其产品线进展的进一步更新以及该公司计划如何弥补疫苗销售持续下滑的问题。

在该公告发布时，BNTX的交易价格为$86.75，交易所为NASDAQ，所属行业为Life Sciences，市值约为$245.6亿。 52周交易区间为$81.20至$124.00。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed BNTX - Latest Insights

BNTX
Apr 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
BioNTech's ADC Trastuzumab Pamirtecan Delivers Strong Phase 2 Efficacy in Endometrial Cancer
Sentiment: Positive
View Wiseek Article
BNTX
Apr 02, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
BioNTech Seeks Shareholder Approval for 50% Potential Dilution via New Authorized Capital
Sentiment: Neutral
View Wiseek Article
BNTX
Mar 24, 2026, 6:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
BioNTech's Gotistobart Shows 54% Reduced Death Risk in Lung Cancer Phase 3 Data at ELCC 2026
Sentiment: Positive
View Wiseek Article
BNTX
Mar 10, 2026, 6:55 AM EDT
Filing Type: 20-F
Importance Score:
7
Annual Report Reveals Pipeline Setbacks, New €450M Liability, and Co-Founder Departure Amidst Mixed Legal Outcomes
Sentiment: Negative
View Wiseek Article
BNTX
Mar 10, 2026, 6:54 AM EDT
Source: Reuters
Importance Score:
8
BioNTech's 2025 Revenue Beats Expectations, Boosted by Bristol Myers Squibb Partnership
Sentiment: Positive
View Wiseek Article
BNTX
Mar 10, 2026, 6:53 AM EDT
Filing Type: 6-K
Importance Score:
8
BioNTech Reports Q4 Loss, Cuts 2026 Revenue Guidance by ~25%, Co-Founders to Depart for New mRNA Venture
Sentiment: Negative
View Wiseek Article
BNTX
Mar 10, 2026, 6:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
BioNTech Posts Steep Q4 Loss, Revenue Plunge on Weak Vaccine Sales
Sentiment: Negative
View Wiseek Article
BNTX
Mar 10, 2026, 6:34 AM EDT
Filing Type: 6-K
Importance Score:
8
BioNTech Co-Founders to Lead New mRNA Innovation Company; BioNTech Sharpens Pipeline Focus
Sentiment: Negative
View Wiseek Article
BNTX
Mar 10, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
BioNTech Targets 15 Oncology Clinical Trials by Year-End, Signaling Robust Pipeline Expansion
Sentiment: Positive
View Wiseek Article
BNTX
Feb 12, 2026, 8:17 AM EST
Filing Type: 144
Importance Score:
8
CEO-affiliated entity files intent to sell $93.8M in BioNTech shares
Sentiment: Negative
View Wiseek Article